These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37435415)

  • 1. Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis.
    Cheplowitz H; Block S; Groesbeck J; Sacknoff S; Nguyen AL; Gopal S
    J Hematol; 2023 Jun; 12(3):105-108. PubMed ID: 37435415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience of patients with sickle cell disease treated with crizanlizumab.
    Chan KH; Buddharaju R; Idowu M
    J Investig Med; 2024 Feb; 72(2):242-247. PubMed ID: 38073007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
    Desai PC; Chen CC; McGuiness CB; Yasuda M; Lee S; Paulose J; He J; Yen G
    Curr Med Res Opin; 2023 Apr; 39(4):555-565. PubMed ID: 36883332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
    Stevens DL; Hix M; Gildon BL
    J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
    [No Abstract]   [Full Text] [Related]  

  • 7. An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
    Jeon WJ; Joung B; Moon JH; Hino C; Park D; Pham B; Castillo DR; Chong E; Kaur S; Grismore C; Cao H
    Hematology; 2023 Dec; 28(1):2215575. PubMed ID: 37227254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
    N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet agents for preventing vaso-occlusive events in people with sickle cell disease: a systematic review.
    Martí-Carvajal A; Abd El Aziz MA; Martí-Amarista C; Solà I
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):234-243. PubMed ID: 31188815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report.
    Alshurafa A; Yassin MA
    Front Med (Lausanne); 2022; 9():1048571. PubMed ID: 36523780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
    Migotsky M; Beestrum M; Badawy SM
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
    Sy SKB; Tanaka C; Grosch K
    Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
    Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
    Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.
    Alkhalifah SA; Alanazi M; Almasaoud MA; Al-Malki HS; Al-Murdhi FM; Al-Hazzaa MS; Al-Mufarrij SM; Albabtain MA; Alshiakh AA; AlRuthia Y
    BMC Emerg Med; 2022 Nov; 22(1):188. PubMed ID: 36447134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
    Kanter J; Ataga KI; Bhasin N; Guarino S; Kutlar A; Lanzkron S; Manwani D; McGann P; Stowell SR; Tubman VN; Yermilov I; Campos C; Broder MS
    Ann Hematol; 2024 Jun; 103(6):1909-1917. PubMed ID: 38642304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.
    Kanter J; Brown RC; Norris C; Nair SM; Kutlar A; Manwani D; Shah N; Tanaka C; Bodla S; Sanchez-Olle G; Albers U; Liles D
    Blood Adv; 2023 Mar; 7(6):943-952. PubMed ID: 36355805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.
    Thom H; Jansen J; Shafrin J; Zhao L; Joseph G; Cheng HY; Gupta S; Shah N
    BMJ Open; 2020 Sep; 10(9):e034147. PubMed ID: 32948541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report.
    Abdulgayoom M; Afana MS; Alshurafa A; Yassin MA
    Clin Case Rep; 2024 May; 12(5):e8585. PubMed ID: 38736574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.